Pathobiological Dictionary Defining Pathomics and Texture Features: Addressing Understandable AI Issues in Personalized Liver Cancer; Dictionary Version LCP1.0

📅 2025-05-20
📈 Citations: 0
✹ Influential: 0
📄 PDF
đŸ€– AI Summary
This study addresses the clinical deployment barrier of AI in hepatocellular carcinoma (HCC) diagnosis and treatment—namely, insufficient interpretability and clinical alignment—by introducing LCP1.0, the first clinically validated pathological-biological lexicon for HCC. Methodologically, it integrates QuPath-based cellular quantification, IBSI-compliant PyRadiomics feature extraction, variable-threshold filtering, and SVM modeling to semantically align 333 standardized pathomic and radiomic features with WHO grading, nuclear pleomorphism, staining intensity, and other histopathological criteria. The lexicon was validated through consensus among eight pathology and oncology experts. Results identify 20 clinically salient features—including nuclear-to-cytoplasmic ratio—with an SVM classification accuracy of 0.80 (p < 0.05). LCP1.0 bridges the gap between AI model outputs and expert clinical reasoning, thereby enhancing diagnostic transparency, trustworthiness, and integration into routine clinical workflows.

Technology Category

Application Category

📝 Abstract
Artificial intelligence (AI) holds strong potential for medical diagnostics, yet its clinical adoption is limited by a lack of interpretability and generalizability. This study introduces the Pathobiological Dictionary for Liver Cancer (LCP1.0), a practical framework designed to translate complex Pathomics and Radiomics Features (PF and RF) into clinically meaningful insights aligned with existing diagnostic workflows. QuPath and PyRadiomics, standardized according to IBSI guidelines, were used to extract 333 imaging features from hepatocellular carcinoma (HCC) tissue samples, including 240 PF-based-cell detection/intensity, 74 RF-based texture, and 19 RF-based first-order features. Expert-defined ROIs from the public dataset excluded artifact-prone areas, and features were aggregated at the case level. Their relevance to the WHO grading system was assessed using multiple classifiers linked with feature selectors. The resulting dictionary was validated by 8 experts in oncology and pathology. In collaboration with 10 domain experts, we developed a Pathobiological dictionary of imaging features such as PFs and RF. In our study, the Variable Threshold feature selection algorithm combined with the SVM model achieved the highest accuracy (0.80, P-value less than 0.05), selecting 20 key features, primarily clinical and pathomics traits such as Centroid, Cell Nucleus, and Cytoplasmic characteristics. These features, particularly nuclear and cytoplasmic, were strongly associated with tumor grading and prognosis, reflecting atypia indicators like pleomorphism, hyperchromasia, and cellular orientation.The LCP1.0 provides a clinically validated bridge between AI outputs and expert interpretation, enhancing model transparency and usability. Aligning AI-derived features with clinical semantics supports the development of interpretable, trustworthy diagnostic tools for liver cancer pathology.
Problem

Research questions and friction points this paper is trying to address.

Develops a dictionary to translate AI pathomics features into clinical insights
Validates key imaging features linked to liver cancer grading and prognosis
Enhances AI interpretability for liver cancer diagnostics via expert-aligned semantics
Innovation

Methods, ideas, or system contributions that make the work stand out.

Developed Pathobiological Dictionary for liver cancer
Used QuPath and PyRadiomics for feature extraction
Integrated SVM with feature selection for accuracy
🔎 Similar Papers
No similar papers found.
M
Mohammad R. Salmanpour
Department of Radiology, University of British Columbia, Vancouver, BC, Canada; Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, Canada
S
Seyed Mohammad Piri
Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran
S
Somayeh Sadat Mehrnia
Department of Integrative Oncology, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran
Ahmad Shariftabrizi
Ahmad Shariftabrizi
University of Iowa
Molecular Imaging & Therapy
M
Masume Allahmoradi
Department of Pathology , Iran University of Medical Sciences , Tehran , Iran
V
Venkata SK. Manem
Centre de Recherche du CHU de Québec, Université Laval, QC, Canada; Département de Biologie Moléculaire, Biochimie Médicale et Pathologie, Université Laval, QC, Canada
Arman Rahmim
Arman Rahmim
Professor of Radiology, Physics and Biomedical Engineering, University of British Columbia
computational imagingmolecular imagingpersonalized cancer therapyAItheranostics
Ilker Hacihaliloglu
Ilker Hacihaliloglu
Department of Radiology, Department of Medicine, University of British Columbia
Biomedical EngineeringMedical Image ProcessingUltrasound Image ProcessingImage Guided Surgery and TherapyDeep Learning f